Read the Beforeitsnews.com story here. Advertise at Before It's News here.
Profile image
By ProactiveInvestors (Reporter)
Contributor profile | More stories
Story Views
Now:
Last hour:
Last 24 hours:
Total:

MGC Pharmaceuticals submits patent application for CimetrA to European IP Office

% of readers think this story is Fact. Add your two cents.


MGC Pharmaceuticals Ltd (ASX:MXC) (LON:MXC) (OTCMKTS:MGCLF) has submitted a patent application for CimetrATM, the Investigational Medicinal Product (IMP) assigned to the company, to the Slovenian Intellectual Property Office (SIPO).

The company submitted its patent application that was accepted by SIPO on May 5, 2021, the priority date for the patent.

CimetrATM has been designed for multiple therapeutic applications including acute and chronic inflammation, COVID-19 and variants of influenza, autoimmune diseases, adverse events resulting from the various forms of cancer therapy, and the promotion of an immune response to bacterial, viral, fungal and parasitic infection – highlighting its versatility as a medicine.

This initial patent application gives MGC Pharma priority to file subsequent patent applications for CimetrATM in other jurisdictions and other IP agencies.

“Bringing to market in multiple jurisdictions”

MGC Pharma expects the patent to be issued within the next 12 months.

MGC Pharma co-founder and managing director Roby Zomer said: “We are delighted that the SIPO recognises the unique formulation of CimetrATM, something we believe will be transformational in the treatment of COVID-19 as well as numerous other conditions.

“The submission of this patent application is an important next step in bringing CimetrATM to market in multiple jurisdictions and ultimately treating people and patients on a global scale whilst Phase III trials for the IMP continue.”

The company continues to progress towards the commencement of its phase III clinical trial for CimetrATM in order to demonstrate the full efficacy and pharmacokinetic profile of the treatment in different variants of the COVID-19 virus.

Novel pharmaceutical composition

The patent provides a nano-micellular pharmaceutical synergetic composition consisting of Curcumin, Boswellia, Artemisinin, and optionally Cannabinoids and/or Nitroxides.

This composition can be manufactured in liquids or in solid pharmaceutically acceptable carriers, has antioxidant, anti-inflammatory, immuno-modulating, anti-viral and anti-cancer properties and can be designed for multiple therapeutic applications, utilising self-nanoemulsifying drug delivery systems (SNEDDS).

The patent sets out the specific antioxidant, anti-inflammatory, immune-modulating, anti-viral, and anti-cancer properties of CimetrATM, designed for multiple therapeutic applications including the treatment of chronic inflammation, severe acute respiratory syndrome coronavirus (SARS-Covid, COVID-19) and heavy variants of influenza, as well as various types of cancer.

This is in addition to its efficacy in relation to the regulation of the human body’s circadian rhythm and homeostasis which promotes an immune response to bacterial, viral, fungal and parasitic infections.

COVID-19 applications

Preclinical and clinical results to date support the pharmaceutical composition of CimetrATM as an effective treatment for addressing anti-inflammation and cytokine over-production (known as cytokine storm) in all tested COVID-19 patients.

Many plant molecules which make up the API are hydrophobic (not water soluble) and thus cannot be readily absorbed by the body.

Once these are encapsulated within the oil-free type IV nano-micellar SNEDDS, the bioavailability of the molecules is increased and the API are emulsified and absorbed more efficiently, resulting in more effective treatment.

The submission of this patent, therefore, has significant implications for the pharmaceutical industry and will ultimately help to increase general drug efficiency.

Story by ProactiveInvestors



Source: http://www.proactiveinvestors.com/companies/news/949736/mgc-pharmaceuticals-submits-patent-application-for-cimetra-to-european-ip-office-949736.html


Before It’s News® is a community of individuals who report on what’s going on around them, from all around the world.

Anyone can join.
Anyone can contribute.
Anyone can become informed about their world.

"United We Stand" Click Here To Create Your Personal Citizen Journalist Account Today, Be Sure To Invite Your Friends.

Please Help Support BeforeitsNews by trying our Natural Health Products below!


Order by Phone at 888-809-8385 or online at https://mitocopper.com M - F 9am to 5pm EST

Order by Phone at 888-388-7003 or online at https://www.herbanomic.com M - F 9am to 5pm EST

Order by Phone at 888-388-7003 or online at https://www.herbanomics.com M - F 9am to 5pm EST


Humic & Fulvic Trace Minerals Complex - Nature's most important supplement! Vivid Dreams again!

HNEX HydroNano EXtracellular Water - Improve immune system health and reduce inflammation

Ultimate Clinical Potency Curcumin - Natural pain relief, reduce inflammation and so much more.

MitoCopper - Bioavailable Copper destroys pathogens and gives you more energy. (See Blood Video)
Oxy Powder - Natural Colon Cleanser!  Cleans out toxic buildup with oxygen! 
Nascent Iodine - Promotes detoxification, mental focus and thyroid health.
Smart Meter Cover -  Reduces Smart Meter radiation by 96%!  (See Video)

Immusist Beverage Concentrate - Proprietary blend, formulated to reduce inflammation while hydrating and oxygenating the cells.

Report abuse
Loading...

Comments

Your Comments
Question   Razz  Sad   Evil  Exclaim  Smile  Redface  Biggrin  Surprised  Eek   Confused   Cool  LOL   Mad   Twisted  Rolleyes   Wink  Idea  Arrow  Neutral  Cry   Mr. Green

MOST RECENT
Load more ...

SignUp

Login

Newsletter

Email this story
Email this story

If you really want to ban this commenter, please write down the reason:

If you really want to disable all recommended stories, click on OK button. After that, you will be redirect to your options page.